From Our Partners
Friday, July 1, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biosecurity

DoD Seeks Medical Countermeasure Manufacturing

by Global Biodefense Staff
June 6, 2016
Bioterrorism Vaccine Countermeasures

Bioterrorism Vaccine CountermeasuresThe U.S. Department of Defense (DoD) is conducting market research to identify vaccine developers who have advanced manufacturing platforms which are adaptable to incorporating known antigens for use as a prophylaxis countermeasure against weaponizable biological agents.

Manufacturers are sought with the capability to develop processes and deliver filled/finished material that is suitable to support non-clinical Investigational New Drug (IND)-enabling studies and for use in humans up through Phase 2 clinical trials under an IND application.

Specifically, the DoD is seeking information from manufacturers with a high level of control over their manufacturing platform processes and, at the appropriate time, the willingness to partner with the DoD to potentially transfer the manufacturing process to the DoD Advanced Development Manufacturing Capability (ADMC) facility, currently residing at Nanotherapeutics Inc in Alachua, Florida.

The DOD intends to use Eastern Equine Encephalitis virus (EEEV) as a test case, and will provide information and materials pertaining to the protective antigens, critical reagents for identity testing, non-clinical challenge models, immunogenicity assays and reagents, and challenge materials.

Further details are available via Solicitation Number: EEEV2016. The response deadline is June 30, 2016.

From Our Partners
Tags: BioterrorismJPEO-CBRNDRFIVaccines

Related Posts

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control
Medical Countermeasures

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Biodefense Industry News
Industry News

Tonix Pharmaceuticals Opens Advanced Development Center for Vaccine Programs

June 20, 2022
Dual Use Research of Concern: NIH to Host Stakeholder Engagement Meeting on Oversight Policies
Biosecurity

Dual Use Research of Concern: NIH to Host Stakeholder Engagement Meeting on Oversight Policies

June 14, 2022
Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine
Medical Countermeasures

Monkeypox Cases Prompt Additional Contracts for Bavarian Nordic Vaccine

May 30, 2022
Load More

Latest News

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

Poliovirus Detected in London Sewage: Response Measures Emphasize Wastewater Surveillance and Vaccination Gaps

June 22, 2022
Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

Monkeypox Diagnostics: CDC Authorizes Five Commercial Lab Companies

June 22, 2022
UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

UK Health Security Agency Widens Monkeypox Vaccine Umbrella for Outbreak Control

June 21, 2022
Influenza Research

New Way to Identify Influenza A Virus Lights Up When Specific Virus Targets are Present

June 20, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC